Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227675 · ClinicalTrials.gov registry record · NA
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional MR
A NA study of Mitral Regurgitation and Mitral Valve Regurgitation, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 162
- Enrollment target
- 20
- Study locations
NCT07227675 is a NA study of Mitral Regurgitation and Mitral Valve Regurgitation that has completed, run by Abbott Medical Devices. The registered enrollment target is 162 participants, below the 1,018-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT07227675, a NA study of Mitral Regurgitation and Mitral Valve Regurgitation, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 162 participants
- Enrollment target
- 20
- Study locations
Study Summary
The COAPT Continued Access Study (CAS) is an extension of the COAPT RCT under the same IDE (G120024). COAPT CAS was a single-arm, prospective, multicenter continued access registry that enrolled heart failure patients with secondary mitral regurgitation who remained symptomatic despite optimal guideline-directed medical therapy (GDMT). The objective of the COAPT CAS is to continue the evaluation of safety and effectiveness of the MitraClip NT System under more "real world" conditions in patients who meet the COAPT inclusion/exclusion criteria and who have national Medicare coverage by the Centers for Medicare and Medicaid Services (CMS).
Conditions Studied
Interventions
- DEVICE MitraClip® NT System
Study Locations (20)
California
- Scripps Green Hospital - La Jolla
- Cedars-Sinai Medical Center - Los Angeles
- El Camino Hospital - Mountain View
- Stanford Hospital and Clinics - Stanford
New York
- NYU Langone Medical Center - New York
- Columbia University Medical Center / New York Presbyterian Hospital - New York
- St. Francis Hospital - Roslyn
Florida
- Mount Sinai Medical Center - Miami
- Tallahassee Memorial Hospital - Tallahassee
Illinois
- Northwestern Memorial Hospital - Chicago
- Rush University Medical Center - Chicago
Missouri
- Saint Luke's Hospital of Kansas City - Kansas City
- Barnes Jewish Hospital - St Louis
North Carolina
- Atrium Health Carolinas Medical Center - Charlotte
- Duke University Medical Center - Durham
Colorado
- University of Colorado Hospital - Denver
Georgia
- Piedmont Hospital Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2017-10-23 |
| Est. Completion | 2024-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07227675
The ClinicalTrials.gov registry entry for NCT07227675 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,018-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target (84% lower). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mitral Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which MitraClip® NT System is the first listed.
NCT07227675 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT07227675 about?
NCT07227675 is a clinical study titled "Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional MR". The COAPT Continued Access Study (CAS) is an extension of the COAPT RCT under the same IDE (G120024). COAPT CAS was a single-arm, prospective, multicenter continued access registry that enrolled heart failure patients with secondary mitral regurgitation who remained symptomatic despite optimal guide...
What is the current status of trial NCT07227675?
This trial is currently completed. It is a NA study. The enrollment target is 162 participants. The study started on 2017-10-23. Estimated completion is 2024-03-31.
What conditions does trial NCT07227675 study?
This clinical trial studies the following conditions: Mitral Regurgitation, Mitral Valve Regurgitation.
What interventions are being tested in trial NCT07227675?
The interventions under investigation include: MitraClip® NT System (DEVICE).
Who is sponsoring clinical trial NCT07227675?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07227675 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mitral Regurgitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System
RECRUITING · NA
-
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
RECRUITING · NA
-
EFS of the CardioMech MVRS
RECRUITING · NA
-
Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock
RECRUITING · NA
-
Cephea Early Feasibility Study
RECRUITING · NA
-
Evaluating Infrasonic Hemodynography
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.